Pregnancy registry for spinal muscular atrophy
Part of Brain & nervous system clinical trials.
This study is a registry that collects information from families who had a pregnancy where the baby was diagnosed with spinal muscular atrophy (SMA) before birth and received treatment during the pregnancy. The goal is to learn more about these cases to improve care and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently pregnant or have been pregnant in the past.
- During that pregnancy, the baby was diagnosed with spinal muscular atrophy (SMA) before birth, based on genetic testing.
- You received treatment for SMA during that pregnancy, such as medication given to you or the baby to help with SMA.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is a registry that collects health information from people with spinal muscular atrophy (SMA). It helps researchers understand the condition better and may support future studies and treatments.
This is a long-term observation study that follows people affected by spinal muscular atrophy (SMA), people who carry the SMA gene but have no symptoms, and families of people with SMA. It helps researchers better understand SMA and related genetic status, which can support future treatment planning.
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
This study collects health information from people with spinal muscular atrophy (SMA) over time to learn more about the disease and how to improve care. It may help researchers understand SMA better.
This study follows people with spinal muscular atrophy (SMA) who have a particular genetic change in the SMN1 gene. It compares long-term outcomes for those who do and do not receive disease-modifying treatments, to better understand what helps over time.
This study is for people who have already received Zolgensma, a gene therapy for spinal muscular atrophy (SMA). It helps us learn more about how safe and effective the treatment is for patients like you.
Hear when a new Spinal Muscular Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.